Status:
COMPLETED
A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This prospective observational study will investigate the effect of tocilizumab on fatigue in participants with moderate to severe rheumatoid arthritis who have an inadequate response to disease-modif...
Eligibility Criteria
Inclusion
- Participants with moderate to severe RA who have been considered and proposed by the rheumatologist to start treatment with Tocilizumab according to his/her clinical judgment and the conditions approved in the Summary of Product Characteristics (SPC).
Exclusion
- Participants previously or currently treated with RoActemra/Actemra in clinical trials
- Absolute neutrophil count less than or equal to (\</=) 2x10\^9 per liter (/L)
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT01462162
Start Date
September 1 2011
End Date
November 1 2013
Last Update
October 31 2016
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Barcelona, Barcelona, Spain, 08035
2
Barcelona, Barcelona, Spain, 08907
3
L'Hospitalet de Llobregat, Barcelona, Spain, 08906
4
Mollet del Vallès, Barcelona, Spain, 08100